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Background: Extracellular matrix (ECM) expansion in noninfarcted myocardium may be an identifiable and treatable disease pathway that 
predisposes individuals to hospitalization for heart failure (HHF), death, or both across the spectrum of left ventricular ejection fraction (EF) and 
heart failure stage. The HHF epidemic is one of the most important and recalcitrant problems confronting contemporary medicine.
Methods: We enrolled 1172 consecutive patients referred for cardiovascular magnetic resonance (CMR) without amyloidosis, stress 
cardiomyopathy, or hypertrophic cardiomyopathy. We quantified ECM expansion in noninfarcted myocardium by CMR measures of the extracellular 
volume fraction (ECV).
results: Over a median of 1.7 years (Q1-Q3, 1.0-2.4 yrs), 55 HHF events and 74 deaths occurred after the baseline CMR scan among 111 
individuals experiencing adverse events (some died after HHF). In multivariable Cox regression models that stratified by hospitalization status and 
heart failure stage and adjusted for age, gender, renal function, myocardial infarction size, and ejection fraction, ECV was associated with HHF (HR 
1.81; 95%CI 1.36-2.41 for every 5% increase in ECV; range 16.6-47.8%). ECV improved the classification of individuals at risk (continuous net 
reclassification improvement 0.34, 95%CI 0.05-0.66; p=0.02) and improved model discrimination (integrated discrimination improvement 0.038, 
95%%CI 0.009-0.076). Similar associations were found for the endpoints of death or either HHF/death.
conclusions: ECM expansion measured by ECV is associated with HHF, death, or both. These data may inform paradigms of cardiac vulnerability 
and risk stratification. Since ECM expansion is reversible, ECM and the fibroblast that regulates it may be attractive therapeutic targets. 
